Contact information
Type
Scientific
Primary contact
Dr Thomas Junghanss
ORCID ID
Contact details
Section of Clinical Tropical Medicine
University Hospital Heidelberg
INF 324
Heidelberg
69120
Germany
-
thomas.junghanss@urz.uni-heidelberg.de
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
A Phase II non-comparative, open label, single-centre study to evaluate the efficacy and host-pathogen response of heat treatment in patients with Buruli ulcer (BU) using a Phase Change Material (PCM) device
Acronym
BU-HEAT-Rx
Study hypothesis
Buruli ulcer (BU) is a chronic necrotising disease of skin and soft tissue caused by Mycobacterium ulcerans. BU has been reported in more than 30 countries, but the major burden lies on children living in remote areas of West Africa associated with swamps and stagnant water bodies.
Heat has been shown to be effective in the treatment of BU in the early 70's. Based on these results, World Health Organization (WHO) guidelines listed the application of heat as a treatment option for BU. However, the heat application devices employed so far were impractical in most endemic countries. We developed and successfully tested in a proof-of-principle-trial (ISRCTN88392614) a heat delivery device which is easy to apply, rechargeable in hot water, non-toxic and non-hazardous to the environment.
Please note that as of 25/11/2009 this trial record has been updated. All updates may be found in the relevant field with the above update date.
Ethics approval
1. Cameroon: National Ethics Committee (Comite National D'Ethique), 30/12/2008
2. Germany: Ethics Committee of the Medical Faculty Heidelberg (Ethikkommission der Medizinischen Fakultaet Heidelberg), 28/01/2009, ref: S-424/2008
Study design
Interventional open-label single-arm single-centre trial
Primary study design
Interventional
Secondary study design
Other
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Buruli ulcer (BU)
Intervention
Phase change material as heat delivery system as part of a bandage which is applied to the BU and the surrounding tissue of the patient. Due to the properties of the bandage patients can move around freely during treatment.
Duration of heat treatment: 4 weeks (small ulcers and without significant oedema) and 6 weeks (large ulcers and/or significant oedema). Total duration of follow-up: 2 years.
Added 25/11/2009:
17 patients have received treatment starting on 20/02/2009 and are now in the follow up period
Along with the original cohort of 17, 5 more cohorts of 16 +/- 2 will be treated over the next 3 years.
Intervention type
Device
Phase
Phase II
Drug names
Primary outcome measure
1. Proportion of patients cured 6 months after completing heat treatment. Cure is defined as complete closure of the wound by epithelialisation or scarification or by skin graft.
2. Proportion of patients recurrence free 12 and 24 months after completing heat treatment
Secondary outcome measures
1. Proportion of patients who were not withdrawn for low compliance or who did not withdraw consent after starting the heat treatment
2. Proportion of patients with adverse events (AEs) being at least considered as possibly related to the heat treatment
3. Proportion of patients showing diminishment of bacterial burden in microbiological assessments of punch biopsies and swabs (i.e. reduction of bacterial counts and changes in bacterial morphology in microscopy and in the quantity of M. ulcerans DNA/RNA in polymerase chain reaction [PCR]) at day 14 and day 28 (punch biopsies) or days 7, 14 and 28 (swabs) after start of treatment compared to reference samples at day 0
4. Proportion of patients showing qualitatively histopathological signs for infiltration and tissue repair at day 14 and day 28 after start of treatment compared to reference sample at day 0
5. Proportion of patients showing increases in immunological response parameters at day 14 and day 28 after start of treatment compared to reference sample at day 0
Overall trial start date
20/02/2009
Overall trial end date
20/05/2011
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Patients (both males and females, age equal or greater than 4 years) with ulcers clinically diagnosed as BU (WHO 2001)
Participant type
Patient
Age group
Child
Gender
Both
Target number of participants
Added 25/11/2009: 100 (6 cohorts of 16 +/- 2)
Participant exclusion criteria
1. Patients with significant other communicable and non-communicable diseases:
1.1. Clinical signs and symptoms of significant communicable diseases other than BU (fever, weight loss, night sweats, persistent cough, jaundice, pulmonary or myocardial dysfunction, central nervous system [CNS] involvement, ascites, pleural effusion)
1.2. Clinical signs and symptoms of significant non-communicable diseases (myocardial, pulmonary, renal, CNS)
2. Patients on chemotherapy for BU (streptomycin, rifampicin)
Recruitment start date
20/02/2009
Recruitment end date
20/05/2011
Locations
Countries of recruitment
Cameroon
Trial participating centre
University Hospital Heidelberg
Heidelberg
69120
Germany
Sponsor information
Organisation
University Hospital Heidelberg (Universitätsklinikum Heidelberg) (Germany)
Sponsor details
Im Neuenheimer Feld 672
Heidelberg
69120
Germany
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Other
Funder name
Volkswagen Foundation (VolkswagenStiftung) (Germany) (ref: I/83 232)
Alternative name(s)
VolkswagenStiftung
Funding Body Type
private sector organisation
Funding Body Subtype
Trusts, charities, foundations (both publically funded and privately funded)
Location
Germany
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2015 results in http://www.ncbi.nlm.nih.gov/pubmed/26486698
2016 results in http://www.ncbi.nlm.nih.gov/pubmed/26486698